BC Innovations | Oct 3, 2019
Targets & Mechanisms

ALS platform trial to put neuroinflammation hypothesis to the test

The largest test of the idea that ALS is driven by neuroinflammation will come from the first collaborative platform trial in the disease, which could blow open the range of pathways and targets in play...
BC Extra | Sep 27, 2019
Clinical News

Avanir’s Alzheimer’s miss weighs on Concert shares

Concert fell 37% on Friday after its partner Avanir reported that AVP-786 missed its primary endpoint and key secondary endpoints in a Phase III trial for mild to severe agitation in patients with Alzheimer's dementia....
BC Extra | Mar 25, 2019
Clinical News

Avanir's AVP-786 meets in Phase III for Alzheimer's agitation

Avanir said one of two doses of AVP-786 met the primary endpoint of improving agitation symptoms in the Phase III 15-AVP-786-301 trial to treat agitation in patients with Alzheimer's dementia. AVP-786 comprises deuterium-modified dextromethorphan --...
BC Extra | Feb 21, 2019
Company News

Management tracks: Mirati, Verastem, RedHill

Oncology company Mirati Therapeutics Inc. (NASDAQ:MRTX) named Faheem Hasnain as chairman. He succeeds Rodney Lappe, who is retiring but will remain a consulting adviser. Hasnain is executive chairman of Gossamer Bio Inc. (NASDAQ:GOSS), which raised...
BC Week In Review | Dec 21, 2018
Company News

Otsuka's Avanir to terminate Onzetra license

OptiNose Inc. (NASDAQ:OPTN) said it received written notice from Avanir Pharmaceuticals Inc. that the latter intends to terminate, effective March 10, a license granting it rights to develop and commercialize migraine drug Onzetra Xsail in...
BC Week In Review | Oct 26, 2018
Financial News

89Bio, a NASH start-up with Teva ties, debuts with $60M

89Bio Ltd. (San Francisco, Calif.) will use its $60 million series A financing to develop therapeutics for non-alcoholic steatohepatitis and other liver and metabolic diseases. The financing was co-led by OrbiMed Israel, OrbiMed US and...
BC Extra | Oct 25, 2018
Financial News

89Bio, a NASH start-up with Teva ties, debuts with $60M

89Bio Ltd. (San Francisco, Calif.) will use its $60 million series A financing to develop therapeutics for non-alcoholic steatohepatitis and other liver and metabolic diseases. The financing was co-led by OrbiMed Israel, OrbiMed US and...
BC Week In Review | Jul 13, 2018
Company News

Otsuka acquiring antibody play Visterra

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said on July 11. The deal gives Otsuka a pipeline based on Visterra's Hierotope...
BC Extra | Jul 11, 2018
Company News

Otsuka acquiring antibody play Visterra

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said Wednesday. The deal gives Otsuka a pipeline based on Visterra's Hierotope platform, which...
BC Extra | Jun 25, 2018
Company News

Management tracks: Nordic Nanovector, Molecular Partners

Cancer company Nordic Nanovector ASA (OSE:NANO) hired Eduardo Bravo as CEO, effective July 2. He was CEO at TiGenix N.V. (NASDAQ:TIG; Euronext:TIG). Protein therapeutics company Molecular Partners AG (SIX:MOLN) said CSO Michael Stumpp has become...
Items per page:
1 - 10 of 457
BC Innovations | Oct 3, 2019
Targets & Mechanisms

ALS platform trial to put neuroinflammation hypothesis to the test

The largest test of the idea that ALS is driven by neuroinflammation will come from the first collaborative platform trial in the disease, which could blow open the range of pathways and targets in play...
BC Extra | Sep 27, 2019
Clinical News

Avanir’s Alzheimer’s miss weighs on Concert shares

Concert fell 37% on Friday after its partner Avanir reported that AVP-786 missed its primary endpoint and key secondary endpoints in a Phase III trial for mild to severe agitation in patients with Alzheimer's dementia....
BC Extra | Mar 25, 2019
Clinical News

Avanir's AVP-786 meets in Phase III for Alzheimer's agitation

Avanir said one of two doses of AVP-786 met the primary endpoint of improving agitation symptoms in the Phase III 15-AVP-786-301 trial to treat agitation in patients with Alzheimer's dementia. AVP-786 comprises deuterium-modified dextromethorphan --...
BC Extra | Feb 21, 2019
Company News

Management tracks: Mirati, Verastem, RedHill

Oncology company Mirati Therapeutics Inc. (NASDAQ:MRTX) named Faheem Hasnain as chairman. He succeeds Rodney Lappe, who is retiring but will remain a consulting adviser. Hasnain is executive chairman of Gossamer Bio Inc. (NASDAQ:GOSS), which raised...
BC Week In Review | Dec 21, 2018
Company News

Otsuka's Avanir to terminate Onzetra license

OptiNose Inc. (NASDAQ:OPTN) said it received written notice from Avanir Pharmaceuticals Inc. that the latter intends to terminate, effective March 10, a license granting it rights to develop and commercialize migraine drug Onzetra Xsail in...
BC Week In Review | Oct 26, 2018
Financial News

89Bio, a NASH start-up with Teva ties, debuts with $60M

89Bio Ltd. (San Francisco, Calif.) will use its $60 million series A financing to develop therapeutics for non-alcoholic steatohepatitis and other liver and metabolic diseases. The financing was co-led by OrbiMed Israel, OrbiMed US and...
BC Extra | Oct 25, 2018
Financial News

89Bio, a NASH start-up with Teva ties, debuts with $60M

89Bio Ltd. (San Francisco, Calif.) will use its $60 million series A financing to develop therapeutics for non-alcoholic steatohepatitis and other liver and metabolic diseases. The financing was co-led by OrbiMed Israel, OrbiMed US and...
BC Week In Review | Jul 13, 2018
Company News

Otsuka acquiring antibody play Visterra

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said on July 11. The deal gives Otsuka a pipeline based on Visterra's Hierotope...
BC Extra | Jul 11, 2018
Company News

Otsuka acquiring antibody play Visterra

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said Wednesday. The deal gives Otsuka a pipeline based on Visterra's Hierotope platform, which...
BC Extra | Jun 25, 2018
Company News

Management tracks: Nordic Nanovector, Molecular Partners

Cancer company Nordic Nanovector ASA (OSE:NANO) hired Eduardo Bravo as CEO, effective July 2. He was CEO at TiGenix N.V. (NASDAQ:TIG; Euronext:TIG). Protein therapeutics company Molecular Partners AG (SIX:MOLN) said CSO Michael Stumpp has become...
Items per page:
1 - 10 of 457